18-Methoxycoronaridine

(-)-18-Methoxycoronaridine (18-MC) is a derivative of ibogaine invented in 1996 by the research team around the pharmacologist Stanley D. Glick from the Albany Medical College and the chemist Martin E. Kuehne from the University of Vermont. In animal studies it has proved to be effective at reducing self-administration of morphine, cocaine, methamphetamine and nicotine.^[1] 18MC is a selective α₃β₄ nicotinic antagonist and, opposed to ibogaine, has no affinity at the α₄β₂ subtype nor at NMDA-channels nor at the serotonin transporter.^[2] 18-MC has not yet been tested in humans. In 2002 the research team started trying to raise funds for human trials, but were unable to secure the estimated $5 million needed.^[3] Efforts to raise funds for future trials are still ongoing.[1]

Additional recommended knowledge

Essential Laboratory Skills Guide

How to quickly check pipettes?

What is the Correct Way to Check Repeatability in Balances?

Its CAS number is [308123-60-6] for the free base and [266686-77-5] for the monohydrochloride.

References

1. ^ S.D. Glick (1996). "18-Methoxycoronaridine, a non-toxic iboga alkaloid congener: effects on morphine and cocaine self-administration and on mesolimbic dopamine release in rats". Brain Res. 719 (1-2): 29-35. PMID 8782860.
2. ^ I.M. Maisonneuve (2003). "Anti-addictive actions of an iboga alkaloid congener: a novel mechanism for a novel treatment". Pharmacol. Biochem. Behav. 75 (3): 607-18. PMID 12895678.
3. ^ Addiction Treatment Strives for Legitimacy. Journal of the American Medical Association. 2002; 288: 3096-3101.

Further reading

1. S.D. Glick (2006). "18-Methoxycoronaridine acts in the medial habenula and/or interpeduncular nucleus to decrease morphine self-administration in rats". Eur. J. Pharmacol.. PMID 16626688.